16th week of 2015 patent applcation highlights part 44 |
Patent application number | Title | Published |
20150105397 | Piperazine derivatives and the use thereof as medicament - The present inventions relate to substituted piperazine derivatives of general formula (I) | 2015-04-16 |
20150105398 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE - A substituted alkenylbenzene compound of formula (4): | 2015-04-16 |
20150105399 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS - Disclosed in the present invention is a 3-cyanoanilinoalkylarylpiperazine derivatives and use thereof in preparing drugs; the 3-cyanoanilinoalkylarylpiperazine derivatives disclosed by the present invention has very useful pharmaceutical properties and good tolerance, especially the use as novel analgesic drugs, novel antidepressants, and novel analgesic and antidepressive drugs. This class of compounds are central analgesics regulating 5-hydroxytrptamine, and also are novel antidepressants regulating 5-hydroxytrptamine. This class of compounds also has less toxic and side effects and a higher safety range. The 3-cyanoanilinoalkylarylpiperazine derivative is a compound shown as formula (III) or free base or salt thereof: | 2015-04-16 |
20150105400 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-β, IL-1β, IL-6 and MCP-1 and the like. | 2015-04-16 |
20150105401 | MLK INHIBITORS AND METHODS OF USE - Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases. | 2015-04-16 |
20150105402 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of allylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 2015-04-16 |
20150105403 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 2015-04-16 |
20150105404 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2015-04-16 |
20150105405 | N-substituted hetero-bicyclic compounds and derivatives for combating animal pests II - The invention relates to N-substituted hetero-bicyclic compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to methods and uses of these N-substituted hetero-bicyclic compounds, and of compositions comprising thereof, for combating and controlling animal pests. Furthermore the invention relates also to pesticidal methods of applying such N-substituted hetero-bicyclic compounds. | 2015-04-16 |
20150105406 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANALGESIC AGENT - The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidinedione compound as a TRPA1 antagonist and an analgesic agent; and use of such composition for treating pain in a subject. | 2015-04-16 |
20150105407 | Substituted Pyrrolo, -Furano, and Cyclopentylpyrimidines Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof - The present invention provides substituted pyrrolo-, furano-, and cyclopentylpyrimidine bicyclic compounds of Formula III, | 2015-04-16 |
20150105408 | CRYSTALLINE Pl3 KINASE INHIBITORS - There is provided inter alia 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in the form of a solid crystalline hydrate and in solid crystalline anhydrous form. There are also provided dry powder pharmaceutical compositions for inhalation containing such solid crystalline forms. | 2015-04-16 |
20150105409 | HDAC INHIBITORS, ALONE OR IN COMBINATION WITH BTK INHIBITORS, FOR TREATING NONHODGKIN'S LYMPHOMA - The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor. | 2015-04-16 |
20150105410 | POLYMORPHIC FORMS OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACE- TIC ACID AND USES THEREOF - Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented. | 2015-04-16 |
20150105411 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS - Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment. | 2015-04-16 |
20150105412 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS - Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone. | 2015-04-16 |
20150105413 | THERAPEUTIC COMPOUNDS - The present invention relates to compounds of formula (I): wherein R | 2015-04-16 |
20150105414 | HAIR GROWTH AND/OR REGROWTH COMPOSITIONS - The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid mixture. The present disclosure also relates to use of the compositions to grow and/or regrow hair and/or prevent hair loss in mammals and particularly in humans. | 2015-04-16 |
20150105415 | TRICYCLIC COMPOUND AND USE THEREOF - The present invention relates to the compound represented by formula (I): | 2015-04-16 |
20150105416 | TREATING POSTOPERATIVE NAUSEA AND VOMITING - Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia. Compositions may include cholinergic receptor agonists, muscarinic receptor agonists, dopamine receptor agonists, MAO inhibitors, serotonin receptor agonists, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin releasing agents, serotonin-norepinephrine-dopamine reuptake inhibitors, opioids, or analgesics. | 2015-04-16 |
20150105417 | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) a compound which modulates the Ras/Raf/Mek pathway for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 2015-04-16 |
20150105418 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 2015-04-16 |
20150105419 | TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-C}PYRIDINES - Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula (I) | 2015-04-16 |
20150105420 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to novel [1,2,4]triazolopyridine compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions. | 2015-04-16 |
20150105421 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUO- ROBENZAMIDE - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 2015-04-16 |
20150105422 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE - (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described. | 2015-04-16 |
20150105423 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION - The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis. | 2015-04-16 |
20150105424 | SMALL VOLUME ORAL TRANSMUCOSAL DOSAGE FORMS CONTAINING SUFENTANIL FOR TREATMENT OF PAIN - Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed. | 2015-04-16 |
20150105425 | Kits and Methods for Treating Post Traumatic Stress Disorder (PTSD) and Hot Flashes - The present invention is directed to kits and methods for the treatment of a patient suffering from post-traumatic stress disorder (PTSD) and/or hot flashes by an administration of a mixture produced by a combination of a long acting local anesthetic combined with clonidine. The combination of the two pharmaceuticals produces a significant increase in duration and speed of onset of sympathetic blockade, increased intensity of the sympathetic blockage as well as the reduction of local anesthetic absorption locally. The combination significantly improves the efficacy, speed of onset and block intensity of a right sided cervical sympathetic ganglion injection (RCSGI) leading to increased length of resolution of PTSD and hot flashes as well as reducing the potential for complications related to absorption of the local anesthetic. | 2015-04-16 |
20150105427 | PEST CONTROL AGENT - A compound of formula (Ie′): | 2015-04-16 |
20150105428 | COMPOSITIONS AND METHODS FOR MODULATING CIRCADIAN SYNCHRONIZATION - The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s). | 2015-04-16 |
20150105429 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS - Compounds of the formula I: | 2015-04-16 |
20150105430 | METHODS OF TREATING OR PREVENTING NEUROPATHIC PAIN - A method treats or prevents neuropathic pain with a synergistically-enhanced analgesic effect at a dose at which a calcium channel α2δ ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a prophylactic agent used in the method includes as effective ingredients a cyclohexane derivative or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel α2δ ligand. | 2015-04-16 |
20150105431 | Nicotine Lozenge Composition - The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form. | 2015-04-16 |
20150105432 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER - The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R | 2015-04-16 |
20150105433 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM - Provided herein are methods for preventing or treating a viral infection in a subject, wherein the viral infection is mediated by a virus comprising one or more viral RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism. The methods comprise administering to a subject an agent that reduces ribosomal protein (Rps25) expression or function. Also provided are methods of inhibiting or promoting ribosomal shunting-mediated translation or non-IRES mediated translation. Also provided are methods of screening for an agent that inhibits or promotes ribosomal shunting-mediated translation or non-IRES mediated translation. | 2015-04-16 |
20150105434 | BIOMARKERS FOR IAP INHIBITOR THERAPY - A method of selecting a subject having cancer for treatment with an IAP inhibitor. | 2015-04-16 |
20150105435 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS - A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins. | 2015-04-16 |
20150105436 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for heating hypoglycemia. The methods are useful for treating diabetes melititus and screening drug candidates for potential efficacy. | 2015-04-16 |
20150105437 | Process for the Preparation of Random Radical Copolymers, and Active Substance Compositions Obtainable Therefrom - A process for the preparation of random radical copolymers which comprises
| 2015-04-16 |
20150105438 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES - This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast. | 2015-04-16 |
20150105439 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES - A pharmaceutical composition, a method of producing same, and a method of providing cancer therapy therein comprising a pharmaceutically acceptable excipient or carrier and a compound Formula 3 as follows: | 2015-04-16 |
20150105440 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION - Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. | 2015-04-16 |
20150105441 | LIM KINASEMODULATING AGENTS FOR NEUROFIBROMATOSES THERAPY AND METHODS FOR SCREENING FOR SAME - Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a LIMK modulating agent. Also disclosed are compounds newly identified to be inhibitors of Merlin-null Schwann cell proliferation and/or survival. | 2015-04-16 |
20150105442 | Nucleic Acid Molecule Capable of Inhibiting Expression of Periostin Gene, method for Inhibiting Expression of Periostin Gene, and Use of Said Nucleic Acid Molecule - Provided is a novel molecule that inhibits the expression of the periostin gene. Also provided are methods of inhibiting the expression of the periostin gene or treating an eye disease using the same. | 2015-04-16 |
20150105443 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR REGULATING EXPRESSION OF GENE HAVING DELIVERING FUNCTION - The invention provides a single-stranded nucleic acid capable of inhibiting expression of a target gene having a delivery function. The nucleic acid contains, from the 5′-side to the 3′-side, a 5′-side region (Xc), a linker region (Lx), an inner region (Z), a linker region (Ly) and a 3′-side region (Yc) in this order, wherein the inner region (Z) is constituted by linkage of the inner 5′-side region (X) and the inner 3′-side region (Y), the 5′-side region (Xc) is complementary to the inner 5′-side region (X), the 3′-side region (Yc) is complementary to the inner 3′-side region (Y), at least one of the inner region (Z), the 5′-side region (Xc) and the 3′-side region (Yc) comprises an expression inhibitory sequence that inhibits expression of a target gene, and at least one of the 5′-terminus, the 3′-terminus, the linker region (Lx) and the linker region (Ly) is bound to a bio-related substance. | 2015-04-16 |
20150105444 | ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN - The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the fibronectin transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with fibrosis. In certain embodiments, such compounds are used to treat one or more symptoms associated with renal fibrosis. | 2015-04-16 |
20150105445 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism. | 2015-04-16 |
20150105446 | Novel Activation and Transfer Cascade for Ubiquitin - A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided. | 2015-04-16 |
20150105447 | FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING - Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2. | 2015-04-16 |
20150105448 | MEANS AND METHODS FOR THE SPECIFIC MODULATION OF TARGET GENES IN THE CNS AND THE EYE AND METHODS FOR THEIR IDENTIFICATION - Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed. | 2015-04-16 |
20150105449 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122 - Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions. | 2015-04-16 |
20150105450 | MULTI-TARGETING SHORT INTERFERING RNAs - The present invention relates to novel short interfering RNA (siRNA) molecules that are multi-targeted. More specifically, the present invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of micro-RNA (miRNA) molecules. In another embodiment, multi-targeting siRNA molecules are designed so that each strand is directed to separate targets. | 2015-04-16 |
20150105451 | TREATMENT OF PARAOXONASE 1 (PON1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PON1 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Paraoxonase 1 (PON1), in particular, by targeting natural antisense polynucleotides of Paraoxonase (PON1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PON1. | 2015-04-16 |
20150105452 | Aptamers to PDGF and VEGF and Their Use in Treating PDGF and VEGF Mediated Conditions - Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs. | 2015-04-16 |
20150105453 | Methods for making and using novel semi-synthetic small molecules for the treatment parasitic disease - Small molecule therapeutics for the treatment of parasitic diseases, in particular, semi-synthetic derivatives of the fugally-derived natural product merulin A for the treatment of African Sleeping Sickness. | 2015-04-16 |
20150105454 | Sparstolonin B Based Pharmaceutical Agent for Neuroblastoma Treatment - Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb | 2015-04-16 |
20150105455 | WINTERIZED CRUDE CANNABIS EXTRACTS AND METHODS OF PREPARATION AND USE - The present technology relates to liquid compositions for use in a personal vaporizer. More particularly, the present technology relates to liquid compositions comprising winterized Cannabis extract, and to methods of administering vaporized winterized Cannabis extract to a subject by inhalation. | 2015-04-16 |
20150105456 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof - The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2. | 2015-04-16 |
20150105457 | LINE LEAF INULA FLOWER LACTONE A AND METHODS FOR PREPARING AND USING THE SAME FOR TREATING MYOCARDITIS - Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of | 2015-04-16 |
20150105458 | LINE LEAF INULA FLOWER LACTONE A AND METHODS FOR PREPARING AND USING THE SAME FOR TREATING MULTIPLE SCLEROSIS - Preparation and application of line leaf | 2015-04-16 |
20150105459 | LICHESTERINIC ACID AND THE DERIVATIVES OF SAME AS PIGMENTATION INHIBITORS - The invention relates to the cosmetic use of a compound chosen from the compounds of formula (A) and the salts of same as an agent for depigmenting the skin and/or keratinous appendages. | 2015-04-16 |
20150105460 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF - Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. | 2015-04-16 |
20150105461 | Metal Delivery Agents and Therapeutic Uses of the Same - The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type. | 2015-04-16 |
20150105462 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT - Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. | 2015-04-16 |
20150105463 | Sodium Pyruvate Oral Rehydration Salt Composition for Treating Hypovolemia or Hyponatration Associated with Hypohydration - Disclosed in the present invention is a sodium pyruvate oral rehydration salt composition for treating hypovolemia or hyponatration associated with hypohydration, said composition containing the following components: (i) 2.0-6.0 parts by weight of sodium pyruvate; (ii) 1.5-17.0 parts by weight of sodium chloride; (iii) 0-2.0 parts by weight of potassium chloride; and (iv) 10.0-50.0 parts by weight of glucose anhydrous or other carbohydrates. The weight of components (i)+(ii)+(iii)+(iv) constitutes 50-100% of the total weight of the composition. | 2015-04-16 |
20150105464 | 4-OXO-2-PENTENOIC ACID AND BRAIN HEALTH - The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline. | 2015-04-16 |
20150105465 | Antiseptic compositions, methods and systems - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 2015-04-16 |
20150105466 | INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS - The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions. | 2015-04-16 |
20150105467 | FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN - The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention. | 2015-04-16 |
20150105468 | Pharmaceutical Composition of Ibuprofen and Tramadol for Ophthalmic Use - The present invention relates to a pharmaceutical composition of ibuprofen and tramadol for ophthalmic use. Said composition is effective and safe for the treatment of ocular inflammation and/or pain associated to different diseases or pathological states which affect the eye area In particular, the ophthalmic composition of the invention is indicated, for example, for the treatment of pain and/or inflammation after eye surgery. | 2015-04-16 |
20150105469 | METHODS OF TREATING UREA CYCLE DISORDERS - The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age. | 2015-04-16 |
20150105470 | PROCESS FOR OBTAINING A MODAFINIL-BASED PHARMACEUTICAL COMPOSITION, RESULTING PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention relates to a novel method for obtaining a pharmaceutical composition based on modafinil. This method consists of solubilizing S modafinil in a fluid in the supercritical state and then after expansion of said fluid, recovering S modafinil by causing it to be absorbed at the surface by a support appearing as granules. Said fluid may be CO | 2015-04-16 |
20150105471 | PARACETAMOL FOR PARENTERAL ADMINISTRATION - The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 μS cm | 2015-04-16 |
20150105472 | ANTIMICROBIAL COMPOSITION - The invention relates to an antimicrobial composition comprising chlorhexidine and pentane-1,5-diol. Such a composition may be used to combat microorganisms. | 2015-04-16 |
20150105473 | AN ANTIBACTERIAL COMPOSITION WITH LOW AMOUNTS OF SURFACTANT AND ANTIBACTERIAL ACTIVES - An antibacterial composition includes at least one surfactant that is less than 6.0 weight percent of the composition and at least one antibacterial active that is less than 0.2 weight percent of the composition. The composition also has a pH between 6.0 and 6.5. The composition also exhibits an efficacy characteristic that results in a logarithmic reduction of at least 2.0 of a bacterial population based on measurements taken from of a user's hand. | 2015-04-16 |
20150105474 | ISOAMYL NITRITE FORMULATIONS - The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations are applicable to cyanide poisoning, H | 2015-04-16 |
20150105475 | POINT OF USE GENERATION OF AMYL NITRITE - The present disclosure relates to devices and methods for the preparation of amyl nitrite formulations at a point of use location from relatively shelf-stable reagents employing acidic cationic exchange resins. | 2015-04-16 |
20150105476 | O/W TYPE COSMETIC COMPOSITION WITH IMPROVED DOSAGE FORM STABILITY - The present invention relates to an O/W type cosmetic composition with improved formulation stability, and more particularly, to an O/W type cosmetic composition comprising a branched polymer having a lipophilic alkyl side chain and an anionic surfactant, as active ingredients for improving formulation stability. | 2015-04-16 |
20150105477 | GEL-LIKE COMPOSITION - An object of the present invention is to provide a gel-like cosmetic material the viscosity of which is not easily reduced even in the presence of an electrolyte, the cosmetic material ensuring an unconventional jelly-like feel when being applied to the skin, and a smooth sensation after being applied to the skin. | 2015-04-16 |
20150105478 | POLYELECTROLYTE COMPLEXES FOR BIOCIDE ENHANCEMENT - The invention relates to a composition comprising a polyelectrolyte complex of a polyanion and a polycation, and comprising at least one biocide. A preferred composition comprises lignosulfonate and chitosan, preferably in relative a amount of from 1:2 to 60:1 (w/w). The invention further relates to methods for generating a composition according to the invention, and to uses of a mixture according to the invention for protecting an agricultural plant or plant part against a pathogen. | 2015-04-16 |
20150105479 | CATALYTICALLY ACTIVE BODY FOR THE SYNTHESIS OF DIMETHYL ETHER FROM SYNTHESIS GAS - The invention relates to a catalytically active body for the synthesis of dimethyl ether from synthesis gas. In particular, the invention relates to an improved catalytically active body for the synthesis of dimethyl ether, whereby the components of the active body comprise a methanol active component and an acid component comprising a zeolitic material being crystallized by means of one or more alkenyltrialkylammonium cation R | 2015-04-16 |
20150105480 | METHOD FOR RECYCLING NOBLE METALS FROM FISCHER-TROPSCH PRODUCTS - A method for recycling a noble metal from Fischer-Tropsch synthesis products. The method includes: 1) filtering a reaction product in a Fischer-Tropsch synthesis reactor by an inner filter; discharging a filtered reaction product to a first filtration buffer tank; separating a gas phase product or a part of a liquid phase product from the reaction product; introducing the liquid-solid two-phase product to a refining filter for product refining; 2) introducing a liquid phase product containing a catalyst slurry to a dynamic filter, collecting the filtered liquid phase product including a waste catalyst and noble metal ions; introducing the liquid phase product to a second filtration buffer tank; and introducing the filtered liquid phase product to the refining filter; and 3) forming a clay filter cake on a filter disk; and refining the products introduced into the refining filter in 1) and 2). | 2015-04-16 |
20150105481 | Curable Compositions and Membranes - A process for preparing a membrane comprising applying a curable composition to a porous support and curing the composition, wherein the composition comprises: a) a curable ionic compound; b) a first crosslinking agent; c) a second crosslinking agent; d) an inert solvent; and e) optionally a free radical initiator; wherein the second crosslinking agent has a melting point below 80° C. Also claimed are the compositions and membranes obtainable by using the process. | 2015-04-16 |
20150105482 | METHOD OF MANUFACTURING A FOAM SHOWING A GRADIENT POISSON'S RATIO BEHAVIOUR - A method of manufacturing a foam having a Poisson's ratio which varies across at least a region of the foam in a gradient distribution involves the steps of: a) providing a housing defining an internal space having an inlet aperture and an outlet aperture; b) providing an open-cell foam of a size and shape configured to fit inside the internal space of the housing; c) positioning the foam inside the internal space of the housing; d) establishing a flow of air through the foam via the inlet and outlet apertures; e) heating the foam to a predetermined temperature whilst maintaining the flow of air through the foam; and f) subsequently cooling the foam whilst continuing to maintain the flow of air through the foam. A foam of such a type is also presented. | 2015-04-16 |
20150105483 | EXPANDABLE COMPOSITE RESIN BEAD - An expandable composite resin bead comprises: a composite resin containing a polyethylene resin and a polystyrene resin; and a blowing agent impregnating the composite resin. The composite resin contains 5 to 20 mass % of the polyethylene resin and 80 to 95 mass % of the polystyrene resin. The blowing agent is an organic physical blowing agent. Furthermore, in the expandable composite resin bead, a predetermined swelling degree in methyl ethyl ketone at a temperature of 23° C. is not lower than 1.25. | 2015-04-16 |
20150105484 | FLAME RETARDANT THERMOPLASTIC ELASTOMERS FOR EXTRUSION OR INJECTION MOLDING - Disclosed are new compositions consisting of mixtures of flame retardants for thermoplastic elastomers with the addition of phosphinate salt and phosphonate oligomers, polymers or copolymers, and optionally additional flame retardants. The compositions exhibit an excellent combination of processing characteristics, thermal and mechanical properties, and are flame retardant. Further disclosed are articles of manufacture produced from these materials, such as fibers, films, coated substrates, moldings, foams, fiber-reinforced articles, wires, and cables including these compositions, or any combination thereof. | 2015-04-16 |
20150105485 | URETHANE FOAM RUBBER AND COMPOSITION FOR FORMING URETHANE FOAM RUBBER - According to the present invention, a urethane foam rubber is constituted with a polymer having a moiety derived from a diisocyanate, and a moiety derived from a polyether polyol, number of atoms composing the shortest path along a bond intervening two NCO groups in at least a part of the diisocyanate is no less than 11, Mw of the polyether polyol is no less than 1,000 and no greater than 4,000, and the polymer exhibits at least one of the following features (i) to (iii): (i) having moieties derived from two or more types of the polyether polyols that are each different in terms of at least one of a weight average molecular weight and an oxyalkylene unit; (ii) having the moiety derived from the polyether polyol that includes two or more types of oxyalkylene units; and (iii) further having a moiety derived from a tri- or higher multi-functional isocyanate. | 2015-04-16 |
20150105486 | OXYGEN SCAVENGING COPOLYMERS MADE FROM CYCLIC ALIPHATIC MONOMERS - A method and system for oxygen molecule scavenging is disclosed. The system employs as a novel copolymer as the reducing agent for oxygen molecules. The copolymer is the polymerization product of cyclic aliphatic monomer and unsaturated functional polymer. | 2015-04-16 |
20150105487 | MIXED SALT SUSPENSION POLYMERIZATION PROCESS AND RESINS AND CATALYSTS PRODUCED THEREOF - This invention relates to no-salt and mixed salt suspension polymerization processes for water-soluble monomers and resins and relates to catalysts produced from the same. | 2015-04-16 |
20150105488 | NOVEL POLYMERIC PHOTOINITIATORS AND PHOTOINITIATOR MONOMERS - The present invention provides polymeric quaternary ammonium photoinitiators being co-polymers of photoinitiator monomers, as well as quaternary ammonium photoinitiator monomer being valuable intermediates in the preparation of such polymeric photoinitiators. Additionally, there is provided a polyacrylate obtained by radical polymerization of at least one acrylate monomer (Ac) in the presence of such polymeric photoinitiators. In the photoinitiator monomers and polymeric photoinitiators, a photoinitiator moiety and a quaternary ammonium are incorporated into the photoinitiator structure. | 2015-04-16 |
20150105489 | DENTAL COMPOSITIONS COMPRISING BISACRYLAMIDES AND USE THEREOF - The invention concerns a dental composition comprising bisacrylamides that are polymerizable by free-radical polymerization and by Michael-addition polymerization with amities. The application of polymerization and addition polymerization with amines opens the possibility to completely reacted materials that have no oxygen inhibited layers. The claimed bisacrylamides have an improved hydrolytic stability. | 2015-04-16 |
20150105490 | RUBBER COMPOSTION, PREPARATION METHOD AND VULCANIZED RUBBER THEREOF - The present application relates to a rubber composition, preparation method and vulcanized rubber thereof. The rubber composition comprises uncrosslinked rubber and rubber particles having crosslinked structure dispersed therein, wherein the rubber particles having crosslinked structure are synthetic rubber particles and/or natural rubber particles, e.g. one or more selected from the group consisting of natural rubber particles, styrene-butadiene rubber particles, carboxylated styrene-butadiene rubber particles, nitrile butadiene rubber particles, carboxylated nitrile butadiene rubber particles, chloroprene rubber particles, polybutadiene rubber particles, silicone rubber particles or acrylic rubber particles, styrene-butadiene-vinylpyridine rubber particles and the like, with an average particle size of 20 to 500 nm and a gel content of 60% by weight or higher, and the uncrosslinked rubber is styrene-butadiene rubber, and wherein the weight ratio of the rubber particles having crosslinked structure to the uncrosslinked rubber is 1:99-20:80. The rubber composition is obtained by mixing the components comprising uncrosslinked rubber latex and latex of rubber particles having crosslinked structure and then coagulating them. The latex of rubber particles having crosslinked structure is a rubber latex after radiation crosslinking. The vulcanized rubber of the rubber composition can be improved simultaneously in rolling resistance, wet skid resistance and wear resistance and thus can be used as high performance vehicle tread rubber. | 2015-04-16 |
20150105491 | Formation of Latex Coagulum Composite for Tire Composition - A tire comprising a rubber composition based on at least an elastomer composite formed by the method of flowing a coagulating mixture of a first elastomer latex comprising a first elastomer and a particulate filler slurry along a conduit; and introducing a second elastomer latex comprising a second elastomer into the flow of the coagulating mixture. | 2015-04-16 |
20150105492 | EPOXY RESIN BLEND DISPERSION AND A PROCESS FOR PREPARING THE DISPERSION - The present invention relates to an aqueous epoxy resin blend dispersion of a high mw epoxy resin and a liquid epoxy resin with a dispersant having an interfacial tension such that a drop of the mixture of the dispersant in a melt of the epoxy resin blend against water is less than 2 dynes/cm, preferably less than 1 dyne/cm, and a process for preparing this epoxy resin blend dispersion. Specifically, the process is a solvent free melt kneading or shearing dispersion process wherein the dispersion is processed at from 50 to 150° C., and the resulting dispersion is stable. | 2015-04-16 |
20150105493 | EPOXY COMPOUND HAVING ALKOXY SILYL GROUP, COMPOSITION COMPRISING SAME, CURED PRODUCT, USE THEREOF AND METHOD FOR PREPARING EPOXY COMPOUND HAVING ALKOXY SILYL GROUP - The present invention relates to an alkoxysilylated epoxy compound, a composite of which exhibits good heat resistance properties, low CTE and high glass transition temperature and not requiring a coupling agent, a composition including the same, a cured product formed of the composition, a use of the cured product, and a method of preparing the epoxy compound having alkoxysilyl group. An epoxy compound having an epoxy group and an alkoxysilyl group, a composition including the epoxy compound, a curing agent, a filler and/or a reaction catalyst, a cured product of the composition, and a use of the composition including an electronic part are provided. In a composite and/or cured product, the epoxy composition forms chemical bonds and exhibits improved heat resistance properties, decreased CTE, and increased glass transition temperature or Tg less. The cured product exhibits good flame retardant property by the introduction of the alkoxysilyl group. | 2015-04-16 |
20150105494 | POLYOLEFIN ASPHALT MODIFIERS, METHODS OF MODIFYING ASPHALT, ASPHALT COMPOSITIONS AND METHODS OF MAKING - An asphalt additive comprising a primary rheology modifying component and a secondary rheology modifying component, and asphalt compositions and products having such additive incorporated therein. The primary rheology modifying component is generally a polymer, and the secondary rheology modifying component may comprise a petroleum micro-wax. | 2015-04-16 |
20150105495 | POLYMERIC ASPHALT MODIFIERS, METHODS OF MODIFYING ASPHALT, ASPHALT COMPOSITIONS AND METHODS OF MAKING - An asphalt additive comprising a primary rheology modifying component and a secondary rheology modifying component, and asphalt compositions and products having such additive incorporated therein. The primary rheology modifying component is generally a polymer, and the secondary rheology modifying component may comprise a petroleum micro-wax. | 2015-04-16 |
20150105496 | FUNCTIONAL GROUP ASPHALT MODIFIERS, METHODS OF MODIFYING ASPHALT, ASPHALT COMPOSITIONS AND METHODS OF MAKING - An asphalt additive comprising a primary rheology modifying component and a secondary rheology modifying component, and asphalt compositions and products having such additive incorporated therein. The primary rheology modifying component is generally a polymer, and the secondary rheology modifying component may comprise a petroleum micro-wax. | 2015-04-16 |
20150105497 | INORGANIC FILLER COATED WITH MOLYBDENUM COMPOUND AND USAGE THEREOF - An inorganic filler coated with molybdenum compound used as an additive is added into a resin mixture in an amount of 20 to 80 wt % of the resin mixture, resulted in that printed circuit boards if made from a laminate or a prepreg containing the resin mixture have properties of a low coefficient of thermal expansion, good heat tolerance and excellent drilling processability. | 2015-04-16 |